Feasibility Study for Repurposing RET Inhibitors
Feasibility Study for Repurposing RET Inhibitors for Treating Cancer Cachexia
Sponsor: University of Oklahoma + Presbyterian Health Foundation
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Mean (± SD) changes in body weight after 12 weeks
Time frame: 12 weeks
Mean (± SD) percentage of doses of selpercatinib taken on time by patient
Time frame: 12 weeks
Secondary Endpoints
Mean (± SD) changes in anorexic behaviors after 12 weeks
Mean (± SD) changes in skeletal muscle while taking selpercatinib
Mean (± SD) changes in Strength outcomes in patients taking selpercatinib
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed and documented locally advanced or metastatic NSCLC, pancreatic ductal adenocarcinoma, or colorectal cancer * Patient is currently receiving platinum-based therapy for cancer treatment * Patients on stable EPI * Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses * At least 18 years-of-age at the time of signature of the informed consent form (ICF) * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2 * Plasma GDF-15 level is at least 1500pg/mL * Life expectancy exceeds 4 months, as judged by investigator * Cachexia, defined as weight loss of \>5% body weight in the past 6 months, OR weight loss of \>2% body weight in the past 6 months with BMI \< 20 Exclusion Criteria: * ECOG Performance Score of 3 or 4 * Is pregnant or plans to become pregnant during study duration (if patient is of childbearing potential) or plans to mak…
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →